New Research Professor MSO in Vaccine Adjuvants at Statens Serum Institut Copenhagen, Denmark

PRESS RELEASE

11 November 2024: Croda Pharma is happy to announce that Dennis Christensen, PhD, Head of Global Research and Development for Vaccine Adjuvant Systems, has been appointed as a part-time Research Professor (MSO) at the Center for Vaccine Research at Statens Serum Institut (SSI).

The Center for Vaccine Research at SSI is internationally recognised for its pioneering work in addressing global health challenges through vaccine research and clinical development. Its efforts focus on development of vaccines targeting infectious diseases such as tuberculosis (TB), chlamydia and group A streptococcus as well as cancer. Central to this mission is the development of innovative adjuvants and delivery systems that enhance vaccine efficacy.

Dr. Christensen’s appointment represents a strategic alignment of SSI’s cutting-edge research and Croda Pharma’s decades of expertise in vaccine adjuvants. During his previous tenure  at SSI, Dr. Christensen was instrumental in the development of the CAF® series of adjuvants, including CAF01, a liposomal adjuvant that boosts T-cell responses and has demonstrated efficacy in vaccines for TB and chlamydia, and CAF09b, a nanoparticulate adjuvant tailored for vaccines requiring enhanced immune responses at mucosal surfaces. These advancements have laid the foundation for next-generation vaccines addressing critical health needs.

In his current role at Croda Pharma, Dr. Christensen leads a dedicated R&D team that serves as a trusted partner for modern vaccine development. Leveraging Croda Pharma’s unique GMP portfolio and over 80 years of expertise, his team collaborates closely with vaccine manufacturers at every stage of the development process. Together, they create tailored solutions that address specific adjuvant needs and accelerate the production of complete adjuvant systems. As a leader in next-generation vaccine adjuvant systems. Croda Pharma combines cutting-edge science and industry-leading expertise to enable the development of tomorrow’s vaccines.

As Research Professor at SSI, Dr. Christensen will focus on advancing SSI’s strategic priorities, including mucosal vaccination and the development of novel delivery formulations for mRNA-based vaccines. His dual role strengthens the collaboration between Croda Pharma and SSI, ensuring the translation of cutting-edge research into impactful clinical applications.

“This appointment underscores our shared vision for the future of vaccine development,” said Dr. Christensen. “By combining SSI’s pioneering research with Croda Pharma’s innovative technologies, we aim to unlock the potential of next-generation vaccines and address some of the world’s most pressing health challenges.”

About Statens Serum Institut (SSI)
Statens Serum Institut (SSI) is a leading international research center under the auspices of the Danish Ministry of Health. SSI is committed to prevent and fight infectious and congenital diseases through research-based monitoring, vaccine research, diagnostics and guidance. The Center for Vaccine Research at SSI is focused on developing and translating groundbreaking research into clinical applications.